Lipocine (NASDAQ:LPCN) Upgraded at Wall Street Zen

Posted by Renee Jackson on Feb 10th, 2026

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) to a sell rating in a research note released on Saturday morning.

Several other brokerages also recently commented on LPCN. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up previously from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.00.

View Our Latest Research Report on LPCN

Lipocine Trading Up 4.7%

LPCN stock opened at $8.89 on Friday. The stock has a 50-day moving average price of $7.00 and a 200-day moving average price of $4.40. Lipocine has a 1-year low of $2.52 and a 1-year high of $12.37. The firm has a market cap of $49.34 million, a PE ratio of -8.72 and a beta of 0.99.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC boosted its holdings in shares of Lipocine Inc. (NASDAQ:LPCN – Free Report) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,450 shares of the specialty pharmaceutical company’s stock after buying an additional 1,374 shares during the period. Geode Capital Management LLC owned approximately 1.13% of Lipocine worth $502,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

(Get Free Report)

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.